Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease

Antiviral Research

Volumn 54, Issue 1, 2002, Pages 29-36

  Ghosh, Arun K ^a   Pretzer, Elizabeth ^b   Cho, Hanna ^a   Hussain, Khaja Azhar ^a   Düzgüneş, Nejat ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Bis Tetrahydrofuran; Human immunodeficiency virus; Protease inhibitor; Structure based design

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; SULFONAMIDE; TETRAHYDROFURAN; TMC 126; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

CELL LINE; HIV CORE PROTEIN P24; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; SAQUINAVIR; SULFONAMIDES; URETHANE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036122884     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00209-1     Document Type: Article

References (39)

1. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
2. Resistance to human immunodeficiency virus type 1 protease inhibitors
3. Antiviral therapy for human immunodeficiency virus infections
4. HIV-protease inhibitors
5. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
6. Synthesis and optical resolution of high affinity P2-ligands for HIV-1 protease inhibitors
7. Potent HIV protease inhibitors: The development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands
8. Cyclic sulfolanes as novel and high affinity ligands for HIV-1 protease inhibitors
9. 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors
10. The development of cyclic sulfolanes as novel and high affinity P2-ligands for HIV-1 protease inhibitors
11. Structure-based design of HIV-1 protease inhibitors: Replacement of two amides and a 10p-aromatic system by a fused bis-tetrahydrofuran
12. Cyclic sulfone-3-carboxamides as novel P2-ligands for Ro 31-8959 based HIV-1 protease inhibitors
13. Nonpeptidal P2-ligands for HIV protease inhibitors: Structure-based design, synthesis and biological evaluations
14. Potent HIV protease inhibitors incorporating high affinity P2-ligands and (R)-hydroxyethylaminosulfonamide isostere
15. Structure based design: Novel spirocyclic ethers as nonpeptidal P2-Ligands for HIV protease inhibitors
16. Antiviral activity of UIC-94-003, a novel inhibitor of the human immunodeficiency virus type-1 protease
17. Infectivity assay (virus yield assay)
18. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins
19. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
20. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
21. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
22. Chromatographic measurement of drug-protein interaction: Determination of HIV protease inhibitor-serum albumin association
23. Active human immunodeficiency virus protease is required for viral infectivity
24. Liposomes modulate human immunodeficiency virus infectivity
25. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes
26. HTLV-III gag protein is processed in yeast cells by the virus pol-protease
27. HIV-1 protease inhibitors and the MDR1 multidrug transporter
28. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies
29. Human immunodeficiency virus type 1 protease inhibitors
30. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
31. Relative potency of protease inhibitors in monocyte/macrophages acutely and chronically infected with human immunodeficiency virus
32. A novel, highly potent human immunodeficiency virus type 1 (HIV-1) protease inhibitor (UIC-94-003)
33. Inhibition of human immunodeficiency virus type-1 replication in macrophages and H9 cells by free or liposome-encapsulated L-689,502, an inhibitor of the viral protease
34. Rational design of peptide-based HIV proteinase inhibitors
35. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
36. In vitro antiviral activity of 14W94 (VX-478) in combination with other antiretroviral agents
37. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
38. L-735, 524: An orally bioavailable human immunodeficiency virus type I protease inhibitor
39. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors